(AOF) – Global Bioenergies announces the strengthening of its gross cash flow, to 14.4 million euros to date (unaudited cash flow), and the extension of its financial visibility until the beginning of 2025 thanks to the receipt of several financings non-dilutive investments from reference partners (Bpifrance, ADEME and the European agency BBI-JU as part of the Horizon 2020 research and innovation program). The company replaces products of petroleum origin with products of natural origin.
The company’s gross cash position was €8.8 million as of December 31, 2022.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.